News

Categories

February 12, 2026

Zymeworks To Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on March 2, 2026

January 27, 2026

Zymeworks Announces Participation in Upcoming Investor Conferences

January 12, 2026

Zymeworks Announces Leadership Appointments and Transitions to Align with Evolution of Corporate Strategy

January 11, 2026

Zymeworks Outlines Strategic Priorities and Outlook for 2026

January 6, 2026

Ziihera® (zanidatamab-hrii) Combinations Achieve Unprecedented Results in First-Line HER2+ Locally Advanced or Metastatic GEA including more than Two Years Median Overall Survival Benefit

December 2, 2025

Zymeworks Announces Participation in Upcoming Conferences

November 24, 2025

Zymeworks Announces Participation in Upcoming Investor Conferences

November 18, 2025

Zymeworks Appoints Scott Platshon as Acting Chief Investment Officer

November 18, 2025

Zymeworks Announces Strategic Initiative to Optimize Value of Licensed Products by Building a Diversified Portfolio of Revenue-Generating Assets

November 17, 2025

Zymeworks Announces Positive HERIZON-GEA-01 Phase 3 Results Supporting Ziihera® (zanidatamab-hrii) as HER2-Targeted Agent-of-Choice and New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma

November 6, 2025

Zymeworks Provides Corporate Update and Reports Third Quarter 2025 Financial Results

November 4, 2025

Zymeworks Presents New Preclinical Data at the Society for Immunotherapy of Cancer Conference